Journal: Cell Death & Disease

Article Title: A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation

doi: 10.1038/cddis.2012.145

Figure Lengend Snippet: HMQ18–22 inhibited cell viability and decreased phosphorylation of VEGFR2, VEGFR1, Akt, PKC α and PLC γ -1 involved in angiogenesis. ( a ) HMQ18–22 decreased cell survival in lovo and HUVEC cells. ( b ) The AlphaScreen signal indicated HMQ18–22 decreased VEGFR phosphorylation. ( c ) Cell were treated with VEGF (50 ng/ml) for 30 min before extracting proteins with RIPA lysis buffer. HMQ18–22 decreased the phosphorylation of VEGFR2(Tyr 1214 ), VEGFR1(Tyr 1333 ), Akt(Tyr 326 ), PKC α (Tyr 657 ) and PLC γ -1(Tyr 771 ) by western blot analysis. On the contrary, the Raf1(Tyr 341 ) phosphorylation was not altered by HMQ18–22. Results were quantified by densitometry analysis of the bands form and then normalization to GAPDH protein. ( d ) Effect of HMQ18–22 on cells transfected with siRNAs targeting of VEGFR2, VEGFR1, Akt, PKC α or PLC γ -1. Quantification of RT-PCR data showed knockdown of VEGFR2, VEGFR1, Akt, PKC α and PLC γ -1; the bottom right panel showed the effect of HMQ18–22 on cells proliferation was attenuated in knockdown cells. Data were expressed as mean values±S.D. ( n =3). * P <0.05, ** P <0.01 versus the untreated control group.

Article Snippet: VEGFR2 kinase was from Carna Biosciences (Kobe, Japan).

Techniques: Amplified Luminescent Proximity Homogenous Assay, Lysis, Western Blot, Transfection, Reverse Transcription Polymerase Chain Reaction

Journal: Cell Death & Disease

Article Title: A novel angiogenesis inhibitor impairs lovo cell survival via targeting against human VEGFR and its signaling pathway of phosphorylation

doi: 10.1038/cddis.2012.145

Figure Lengend Snippet: HMQ18–22 inhibited tumor growth in nude mice bearing human colon cancer xenografts. ( a ) The representative xenografts of lovo human colon cancer in mice. ( b ) HMQ18–22 decreased the phosphorylation of VEGFR2(Tyr 1214 ), VEGFR1(Tyr 1333 ), Akt(Tyr 326 ), PKC α (Tyr 657 ) and PLC γ -1(Tyr 771 ) in the tumor tissues by western blot analysis. ( c ) Quantitation data of ( b ). Data were expressed as mean values±S.D. ( n =3). ** P <0.01 versus the untreated control

Article Snippet: VEGFR2 kinase was from Carna Biosciences (Kobe, Japan).

Techniques: Western Blot, Quantitation Assay